Europe’s Payers Bake Indication-Specific Pricing Into Benefit Assessments
Executive Summary
European countries haven’t grappled with indication-specific pricing, mostly because they haven’t had to.
You may also be interested in...
Pricing By Indication Takes Hold, Despite Hurdles
Indication-based drug pricing is one mechanism for pegging price to value. It will be tough to implement in the US without systemic change, but PBMs have plenty of incentives to make it work.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.